Coldstream Capital Management Inc Crinetics Pharmaceuticals, Inc. Call Options Transaction History
Coldstream Capital Management Inc
- $4.64 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CRNX
# of Institutions
245Shares Held
88.2MCall Options Held
32.6KPut Options Held
7.7K-
Vanguard Group Inc Valley Forge, PA9.31MShares$310 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.89MShares$230 Million0.05% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.24MShares$208 Million2.28% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$208 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.11MShares$170 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.79B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...